2.41
price down icon3.60%   -0.09
after-market Dopo l'orario di chiusura: 2.28 -0.13 -5.39%
loading
Precedente Chiudi:
$2.50
Aprire:
$2.52
Volume 24 ore:
227.91K
Relative Volume:
0.91
Capitalizzazione di mercato:
$141.91M
Reddito:
-
Utile/perdita netta:
$-46.12M
Rapporto P/E:
-2.7887
EPS:
-0.8642
Flusso di cassa netto:
$-41.02M
1 W Prestazione:
-6.95%
1M Prestazione:
+7.11%
6M Prestazione:
+47.85%
1 anno Prestazione:
+50.62%
Intervallo 1D:
Value
$2.28
$2.52
Intervallo di 1 settimana:
Value
$2.28
$2.7499
Portata 52W:
Value
$1.165
$2.815

Inflarx N V Stock (IFRX) Company Profile

Name
Nome
Inflarx N V
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
66
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-08
Name
Ultimi documenti SEC
Name
IFRX's Discussions on Twitter

Confronta IFRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IFRX
Inflarx N V
2.41 141.91M 0 -46.12M -41.02M -0.8642
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.11 104.84B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
718.15 78.92B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
621.29 37.15B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.28 30.22B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
115.79 27.76B 3.30B -501.07M 1.03B -2.1146

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-04-05 Aggiornamento Guggenheim Neutral → Buy
2022-02-28 Downgrade Guggenheim Buy → Neutral
2021-10-28 Aggiornamento Raymond James Outperform → Strong Buy
2021-03-11 Aggiornamento Guggenheim Neutral → Buy
2020-11-06 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-10-08 Iniziato H.C. Wainwright Buy
2020-06-17 Iniziato BTIG Research Buy
2020-04-30 Aggiornamento Raymond James Mkt Perform → Outperform
2019-06-05 Downgrade BMO Capital Markets Outperform → Market Perform
2019-06-05 Downgrade Guggenheim Buy → Neutral
2019-06-05 Downgrade JP Morgan Overweight → Underweight
2019-06-05 Downgrade Robert W. Baird Outperform → Neutral
2019-06-05 Downgrade SunTrust Buy → Hold
2019-01-29 Iniziato Robert W. Baird Outperform
2018-12-10 Iniziato Credit Suisse Outperform
2018-07-13 Iniziato BMO Capital Markets Outperform
2018-06-28 Iniziato Raymond James Outperform
2018-06-28 Iniziato SunTrust Buy
2018-02-08 Iniziato B. Riley FBR, Inc. Buy
Mostra tutto

Inflarx N V Borsa (IFRX) Ultime notizie

pulisher
Dec 30, 2024

InflaRx (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Dec 29, 2024
pulisher
Dec 24, 2024

US Penny Stocks To Watch In December 2024 - Simply Wall St

Dec 24, 2024
pulisher
Dec 24, 2024

Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy - Investing.com Nigeria

Dec 24, 2024
pulisher
Dec 20, 2024

InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times

Dec 20, 2024
pulisher
Dec 20, 2024

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug - TipRanks

Dec 20, 2024
pulisher
Dec 20, 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewswire

Dec 20, 2024
pulisher
Dec 20, 2024

InflaRx Launches Phase 2a Trial for Billion-Dollar Skin Disease Drug INF904 - StockTitan

Dec 20, 2024
pulisher
Dec 06, 2024

InflaRx (NASDAQ:IFRX) Trading 3.8% HigherHere's Why - MarketBeat

Dec 06, 2024
pulisher
Nov 22, 2024

InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 22, 2024
pulisher
Nov 20, 2024

Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com Canada

Nov 20, 2024
pulisher
Nov 19, 2024

10 Best German Stocks To Buy Now - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Insider Monkey

Nov 19, 2024
pulisher
Nov 15, 2024

InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St

Nov 14, 2024
pulisher
Nov 12, 2024

InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance

Nov 10, 2024
pulisher
Nov 09, 2024

InflaRx expects cash to fund operations into 2026 - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 08, 2024
pulisher
Nov 07, 2024

InflaRx (IFRX) to Release Earnings on Friday - Defense World

Nov 07, 2024
pulisher
Nov 01, 2024

InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire

Oct 31, 2024
pulisher
Oct 22, 2024

Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World

Oct 22, 2024
pulisher
Oct 14, 2024

InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat

Oct 14, 2024
pulisher
Sep 26, 2024

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News

Sep 25, 2024
pulisher
Sep 05, 2024

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

Sep 05, 2024

Inflarx N V Azioni (IFRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.24
price down icon 0.60%
$21.47
price up icon 2.24%
$356.33
price down icon 1.08%
$42.18
price up icon 0.43%
$184.71
price up icon 0.49%
$115.79
price up icon 0.42%
Capitalizzazione:     |  Volume (24 ore):